Taiwan
· Delayed Price · Currency is TWD InnoPharmax Company Description
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan.
The company’s core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents consisting of gadopentetate dimeglumine and gadodiamide; oncology agents comprising Innomustine and Immurin; and Inpheno tablets for rare diseases.
In addition, the company provides MUCR system, OralPas, and OralPas Pro technology platform. Its product pipeline comprises D07001, which is in phase I trial for treatment of tumor; C08001, which is in phase lll for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction; D07002, which is in pilot BE trial used as a supplement for phenylketonuria; and C07001, which is in pilot BE trial for the treatment of parkinson’s disease; N11001, which is in pilot BE as urology agents; and D0131502 and D0051301 as contrast agents and is in formulation.
The company was founded in 1994 and is based in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Weihua Hao |
Contact Details
Address: No. 20 and No. 22, Lane 478 Taipei, 11492 Taiwan | |
| Phone | 886 2 8797 7607 |
| Website | innopharmax.com |
Stock Details
| Ticker Symbol | 4172 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004172002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Weihua Hao | Chief Executive Officer |